To hear about similar clinical trials, please enter your email below
Trial Title:
Dysregulation of the C/EBPa Pathway in Human Lung Cancer and Search for New Biomarkers and/or Therapeutic Targets
NCT ID:
NCT01619501
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
The overall goal of this research is to enhance the investigators understanding of the
pathways involved in lung cancer, and to identify new biomarkers and/or therapeutic
targets. By comparing gene expression between normal lung tissue and tumors growing in
lung-specific C/EBPa KO mice, the investigators have identified the Bmi-1 proto-oncogene
as being abnormally upregulated in C/EBPa-deleted tumors. Subsequently, the investigators
have validated this observation in human lung cancer, implicating the investigators KO
mice are an effective discovery tool for lung cancer research. Through similar
approaches, the investigators have already identified (Sonic Hedgehog, SHH), and plan to
identify other pathways which are abnormally regulated in C/EBPa-/- tumors. In parallel,
the investigators will proceed to define the clinical relevance of the SHH pathway and
the other newly-discovered molecular aberrations, by analyzing their expression and
correlate it to C/EBPa expression on the samples of patients with NSCLC at NUHS. If the
investigators preliminary data on Bmi-1 will be confirmed, this proto-oncogene may
generate useful correlates that could be used in diagnosis and treatment of lung cancer,
as well as identify new prognostic/predictive markers in lung cancer. Similarly, SHH
pathway-components may behave as potential biomarkers and therapeutic tools for
C/EBPa-related lung cancers.
This proposal seeks to test the hypothesis that pathways which are dysregulated in lung
tumors growing in a lung-specific C/EBPa KO model can be utilized as discovery tools to
identify genes involved in human lung cancer pathogenesis.
Criteria for eligibility:
Study pop:
Archived samples from the Department of Pathology (for IHC, FISH) and the Tissue
Repository (for fresh tumor samples) at NUHS
Sampling method:
Probability Sample
Criteria:
Inclusion Criteria:
Patients with lung cancer
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Nationa University Hospital
Address:
City:
Singapore
Country:
Singapore
Status:
Recruiting
Contact:
Last name:
Ross Soo
Phone:
+65 6779 5555
Investigator:
Last name:
Ross Soo
Email:
Principal Investigator
Start date:
April 2012
Lead sponsor:
Agency:
National University Hospital, Singapore
Agency class:
Other
Source:
National University Hospital, Singapore
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT01619501
